The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.
 
Saroj Vadhan-Raj
Honoraria - Tesaro
Consulting or Advisory Role - Amgen; BeyondSpring Pharmaceuticals; DARA BioSciences; Enzychem Lifesciences; Hospira; Janssen; Novartis; Pfizer; Sandoz; Shionogi
Research Funding - American Regent; American Regent (Inst); Amgen; Amgen (Inst); Janssen; Janssen (Inst); Tesaro; Tesaro (Inst)
 
Mairead Geraldine McNamara
Consulting or Advisory Role - Ipsen; Shire; Sirtex Medical
Speakers' Bureau - Nucana
Research Funding - Ipsen; Nucana; SERVIER
Travel, Accommodations, Expenses - Bayer
 
Marino Venerito
Honoraria - Bayer; Merck Serono; Nordic Bioscience
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; Lilly; MSD; Nordic Bioscience
Research Funding - Sirtex Medical
Expert Testimony - Lilly
 
Hanno Riess
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson; Pfizer
Speakers' Bureau - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Leo Pharma; Pfizer
Research Funding - Bayer; Leo Pharma
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Gritstone Bio; MedImmune; Roche/Genentech
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Xiao Zhou
Research Funding - Amgen; TerSera
 
Ujjwala Vijapurkar
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Simrati Kaul
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Peter Wildgoose
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Alok A. Khorana
Honoraria - AngioDynamics; Bayer; Halozyme; Janssen; Pfizer; Pharmacyte Biotech
Consulting or Advisory Role - Bayer; Halozyme; Janssen; Pfizer; Pharmacyclics; Pharmacyte Biotech; Seagen
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Leap Oncology (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Janssen; Pfizer